Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung



Common side effects of clofarabine (CFB) are liver toxicity, particularly a transient elevation of transaminases and skin toxicity. We studied the correlation of pharmacokinetic (PK) parameters with these toxicities and the efficacy of CFB in patients with relapsed or refractory acute myeloid leukemia. Clofarabine PK parameters showed large inter-individual variability. A higher CFB area under the curve was significantly associated with higher transaminase levels (p =.011 for aspartate aminotransferase (AST), adjusted for age, sex, cumulated CFB dosage, baseline AST, and glomerular filtration rate (GFR)). No significant association could be found between maximum concentration and the liver toxicity parameters. The occurrence of skin toxicity and the response to re-induction chemotherapy evaluated at day 15 were also not associated with PK. In conclusion, a higher individual CFB exposure is associated with increased liver toxicity reflected by elevated liver enzymes, without having an impact on anti-leukemic efficacy.


Seiten (von - bis)2865-2874
FachzeitschriftLeukemia and lymphoma
PublikationsstatusVeröffentlicht - 2 Dez. 2017

Externe IDs

Scopus 85019179236
PubMed 28509593
researchoutputwizard legacy.publication#78646
ORCID /0000-0003-1526-997X/work/142247234


Ziele für nachhaltige Entwicklung


  • acute myeloid leukemia, Clofarabine, liver toxicity, pharmacokinetics, skin toxicity